Venture Capital

Psychedelic Stocks: Atai Life Sciences IPO Seeks To Raise $100 Million


Atai Life Sciences, which supports psychedelic drug developers seeking new ways to treat mental illness, hopes to raise $100 million in an initial …

Read more

Show More

Related Articles

Back to top button